The Rationale Behind CheckMate-275 in Metastatic Bladder Cancer

For patients who underwent radical cystectomy for bladder cancer, those with lower net worth incurred higher costs posttreatment.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.